Literature DB >> 24382432

Epigenetics in breast cancer.

C Atalay1.   

Abstract

Epigenetic information has recently gained the attention of researchers and epigenetics in breast cancer is still an evolving area of research. Epigenetic modifications such as DNA methylation and histone acetylation have been thoroughly evaluated in breast cancer. New methods to detect epigenetic changes with higher specificity have been developed. These methods are utilized to find new markers for the diagnosis and prognosis of breast cancer. In addition, epigenetic modifications are assumed as new targets in the treatment of breast cancer and new drugs alone or in combination with conventional therapies such as chemotherapy or hormone treatment are being tested in clinical trials.

Entities:  

Mesh:

Year:  2013        PMID: 24382432

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  9 in total

1.  Tumor DNA hypomethylation of LINE-1 is associated with low tumor grade of breast cancer in Tunisian patients.

Authors:  Hayet Radia Zeggar; Alexandre How-Kit; Antoine Daunay; Ilhem Bettaieb; Mourad Sahbatou; Khaled Rahal; Olfa Adouni; Amor Gammoudi; Hayet Douik; Jean-François Deleuze; Maher Kharrat
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

2.  Clinical impact of PTEN methylation status as a prognostic marker for breast cancer.

Authors:  Amal Ramadan; Maha Hashim; Amr Abouzid; Menha Swellam
Journal:  J Genet Eng Biotechnol       Date:  2021-05-10

Review 3.  Developing DNA methylation-based diagnostic biomarkers.

Authors:  Hyerim Kim; Xudong Wang; Peng Jin
Journal:  J Genet Genomics       Date:  2018-02-17       Impact factor: 5.723

Review 4.  Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.

Authors:  Ruixue Huang; Ping Ding; Fei Yang
Journal:  Drug Des Devel Ther       Date:  2015-09-18       Impact factor: 4.162

5.  Relationships between p14ARF Gene Methylation and Clinicopathological Features of Colorectal Cancer: A Meta-Analysis.

Authors:  Zhangjian Zhou; Hao Zhang; Jianguo Lai; Dongmei Diao; Wenhan Li; Chengxue Dang; Yongchun Song
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

6.  PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.

Authors:  Magdalena Absmaier; Rudolf Napieralski; Tibor Schuster; Michaela Aubele; Axel Walch; Viktor Magdolen; Julia Dorn; Eva Gross; Nadia Harbeck; Aurelia Noske; Marion Kiechle; Manfred Schmitt
Journal:  Int J Oncol       Date:  2018-01-08       Impact factor: 5.650

7.  Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells.

Authors:  Andrew Zheng; Michelle Bilbao; Janhvi Sookram; Kimberly M Linden; Andrew B Morgan; Olga Ostrovsky
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

Review 8.  The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.

Authors:  Yunshu Su; Xiaoli Wang; Jun Li; Junming Xu; Lijun Xu
Journal:  Drug Des Devel Ther       Date:  2015-10-01       Impact factor: 4.162

9.  The association of PTEN hypermethylation and breast cancer: a meta-analysis.

Authors:  Shanshan Luo; Jiansi Chen; Xianwei Mo
Journal:  Onco Targets Ther       Date:  2016-09-12       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.